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Background: The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical
data and biomaterials from patients suffering from chronic diseases (so called “Pearls”) are collected according to
harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis,
differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer’s disease.
The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as
baseline descriptive variables, including their biomarker profile.
Methods: The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic
with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data
and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients
have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients,
respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with
dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%).
Discussion: The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and
biomaterials of more than 1000 patients with cognitive impairments. The project has started with data
analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific
research questions that can be answered by this unique dataset.
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The parelsnoer institute
The Parelsnoer Institute (PSI; www.string-of-pearls.org)
is a collaboration of the eight Dutch University Medical
Centers (UMCs), designed to create an infrastructure for
collection of clinical data and biomaterial from patients
with chronic diseases. The conceptual starting point for
PSI is the idea that clinical practice and research can
mutually strengthen each other. By providing a har-
monized infrastructure for the clinical evaluation of* Correspondence: p.aalten@maastrichtuniversity.nl
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unless otherwise stated.patients, data collection and storage of data in a cen-
tralized database, PSI enables the use of multicenter
clinical data to answer research questions targeted to
improve patient care. PSI takes advantage of the Dutch
context, where it is relatively easy to achieve nationwide
coverage of disease populations because of the close con-
nections. Initially, eight patient cohorts were created, sym-
bolized by “Pearls”. Besides Neurodegenerative diseases,
in particular dementia, the Pearls include stroke, type
2 diabetes mellitus, hereditary colorectal cancer, inflam-
matory bowel diseases (Crohn’s disease and ulcerative col-
itis), leukaemia, renal failure, and rheumatoid arthritis and
arthrosis.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Dementia is one of the major health care challenges of
the 21st century. There are currently more than 35 mil-
lion people affected with dementia worldwide, of which
Alzheimer's disease (AD) is the most common type [1].
Other types of dementia include vascular dementia, de-
mentia with Lewy bodies, frontotemporal dementia and
more rare variants [2,3]. To date, there is no cure for
AD or any of the other types of dementia. In fact, we are
only just starting to understand the aetiology and disease
course of these diseases. Research in AD has long time
been hampered by the fact that neither plaques nor tan-
gles (nor any of the proteins involved in other types of
dementia) could be measured during life. The develop-
ment of biomarker assays as diagnostic tests in cerebro-
spinal fluid (CSF) and amyloid imaging using PET
has been a great breakthrough, together with structural
imaging using MRI, acting as a catalyst for AD research.
The biomarkers have been used to develop a hypothetical
model, which serves to test hypotheses regarding the order
of events leading to AD dementia [4,5]. In addition, there
is increasing evidence that some biomarkers can be used
as early diagnostic markers in the continuum of AD. Re-
sults from several large studies have demonstrated that a
combination of CSF biomarkers and neuroimaging mea-
sures is useful in predicting the likelihood of developing
AD [6]. This has resulted in their incorporation in new
diagnostic criteria, as a means to provide evidence for the
presence of Alzheimer pathology [7-9]. It is now widely
recognized that AD has a long pre-dementia stage, as brain
changes start to accumulate as early as 15 to 20 years
before dementia onset [10]. Mild cognitive impairment
(MCI) refers to a stage where memory impairment can be
objectified, but the patients’ daily functioning is still intact.
In university memory centres, patients with MCI have a
mean annual conversion rate of 10% to dementia, mostly
AD [11]. With the use of biomarkers, it is possible to
make a better prediction of conversion to AD, though
still far from perfect [12]. Preclinical AD is the pro-
posed terminology to describe the stage when the earliest
brain changes have begun, but there are no clinical
signs yet [13].
Aim pearl neurodegenerative diseases
The aim of the Pearl Neurodegenerative diseases is to
provide an infrastructure for the study of biomarkers for
early diagnosis predicting clinical decline and incident
dementia in those who are not demented yet, and for
differential diagnosis and discriminating AD from other eti-
ologies. The evaluation of a broad spectrum of patients,
representing a tertiary memory clinic population, allows an-
swering both questions. This is achieved by establishing a
biobank containing blood, CSF, DNA with available exten-
sive clinical phenotyping of patients, neuropsychologicaltests, and brain MRI. The data collection is completed by
data from annual follow-up assessments.
In this paper, we describe the design and methods of
the Pearl Neurodegenerative diseases as well as baseline
descriptive variables. In addition, we extracted DNA and
CSF from the biobank, and determined APOE genotype,
and CSF concentrations of amyloid-beta 1–42 (ab42), total
tau and tau phosphorylated at threonine 181 (ptau).
Methods
Study design
PSI is a collaboration of all eight UMCs in the Netherlands
(University of Maastricht, Amsterdam (Free University
and Amsterdam Medical Center), Rotterdam, Leiden,
Groningen, Utrecht, and Nijmegen), and is jointly fi-
nanced by the Dutch government and the eight Dutch
UMCs. The Pearl “Neurodegenerative diseases” is a pro-
spective, multi-center cohort study, focusing on tertiary
memory clinic patients with cognitive problems including
dementia. The memory clinics are embedded at the
department of psychiatry (1 center), neurology (5 centers),
or geriatrics (2 centers). Patients are enrolled from March
2009 and initially followed annually for two years. The
goal was to include 100 patients per center, resulting in a
database of 800 patients.
Patients
In order to include the whole cognitive spectrum from
subjective cognitive complaints to dementia, broad inclu-
sion criteria were chosen. Inclusion criteria included pa-
tients referred to a memory clinic for the evaluation of
cognitive problems, with a clinical dementia rating scale
(CDR) [14] score of 0, 0.5, or 1, and a Mini Mental State
Examination (MMSE) [15] of 20 or higher. Exclusion
criteria were: Normal Pressure Hydrocephalus, Morbus
Huntington, recent Transient Ischemic Attack (TIA) or
Cerebrovascular Accident (CVA) (<2 years), TIA/CVA
followed by cognitive decline (within three months), his-
tory of schizophrenia, bipolar disorder or psychotic symp-
toms not otherwise specified or previous treatment for
these diseases, current major depressive disorder (DSM
IV), cognitive problems due to alcohol abuse, brain tumor,
epilepsy, encephalitis, mental incompetence for deciding
participation, absence of a reliable informant, or the ex-
pectation that a follow-up assessment after one year was
not possible.
Baseline minimal dataset
At baseline, each center collected a harmonized minimal
dataset, consisting of variables highly relevant for the
early diagnosis of neurodegenerative diseases. Data were
collected according to Standard Operating Procedures
(SOPs) specifically defined for the Pearl “Neurodegener-
ative diseases”.
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cognitive assessment. In addition, a MRI of the brain was
made and blood samples and CSF samples (optional) were
collected for biobanking purposes. Table 1 gives an over-
view of the data collection per assessment.Clinical data
Data were collected on demographics, medical history,
medication use, and family history from an open inter-
view with both patient and caregiver. In addition, a clin-
ician performed a physical examination. Finally, clinical
assessment included several scales and questionnaires,
as well as a standardized cognitive assessment.Demographic data
Demographic variables included age, gender, educational
level, ethnicity, and marital status.Physical examination
The physical examination included the measurement of
blood pressure, weight, height, gait disturbances, and extra-
pyramidal symptoms. In addition, data on smoking behav-
ior, and alcohol consumption habits were collected.Syndromal diagnosis
The diagnosis of dementia was based on DSM-IV criteria
[16]. Etiological diagnoses were made according to stan-
dardized clinical criteria for AD (NINCDS-ADRDA criteria,
[16,17], vascular dementia (NINDS-AIREN criteria, [18],
frontotemporal dementia [3], and Lewy body dementia [2].Box 1 Standardized cognitive test battery
Test Cognitive domain(s)
Mini Mental State Examination1 Global cognition
15 Word-Auditory Verbal Learning
Test2
Episodic memory
Visual Association Test, short version3 Implicit associative visual learning
Digit-Span of the WAIS III (forward Working memoryMedical history and medication use
Data were collected on medical conditions, such as neuro-
logical problems, cardiovascular problems, cerebrovascu-
lar problems, endocrine diseases, psychiatric diseases, and
somatic diseases. In addition, data on the current use of
medication (name, dose, frequency, and Anatomical
Therapeutic Chemical (ATC)-code) were collected.Table 1 Flowchart data collection
Baseline 1-year FU 2-year FU
Informed consent X
Clinical data X X X
Cognitive assessment X X X
Scales and questionnaires X X X




DNA: Deoxyribonucleic Acid, MRI: Magnet Resonance Imaging, CSF:
Cerebrospinal fluid.Family history
Data were collected on the family history of diagnoses of
dementia, Parkinsonism, and Amyotrophic Lateral Sclerosis,
including the number of first and second-degree relatives,
the specification of the relatives, and their age at time of
diagnosis.
Scales and questionnaires
The CDR, rated by the physician, provided a global rating of
dementia severity. The 15-item Geriatric Depression Scale
(GDS-15) [19] and the Euro-Quality of life-5 Dimensions
[20] were used to provide self-reported information about
depressive symptoms and quality of life. The 4-item ques-
tionnaire on Subjective Cognitive Functioning (SCF) gave in-
formation about the patient’s experience of his change in
cognitive functioning. A semi-structured interview with a fa-
miliar caregiver provided information about the presence of
neuropsychiatric symptoms and the daily functioning. The
frequency and severity of neuropsychiatric symptoms were
measured using the Neuropsychiatric Inventory (NPI) [21].
Basic and instrumental activities in daily life were assessed
with the Disability assessment for Dementia (DAD) [22].
Cognitive assessment
Data about the start and course of the cognitive com-
plaints were collected. The cognitive assessment consisted
of a standardized battery of cognitive tests. All tests were
performed according to the SOP for cognitive assessment.
The tests were harmonized across all centers. An overview
of the tests used and their corresponding cognitive do-
mains is presented in Box 1.and backward)4
Fluency, 60 seconds (animals)5 Verbal word fluency/semantic
memory
Letter Digit Substitution Test,
60 seconds6
Information processing speed
Stroop Color Word Test (SCWT)7,
10x10 items, 4 colors
Information processing speed,
attention and respons inhibition/
executive functioning
Trail Making Test (TMT) (Part A and B)8 Information processing speed,
attention and concept shifting/
executive functioning
Optional: dot counting and
incomplete letters of the Visual
Object and Space Perception Battery
Visual perception
References: 1 [15]; 2 [23,24]; 3 [25]; 4 [26]; 5 [27]; 6 [28]; 7 [29,30]; 8 [31].
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MRI
A standardized MRI protocol was defined in the SOP
for brain imaging. Box 2 gives an overview of the MRI
sequences included in the protocol. Acquisition of the
MR images was performed at each individual site using
MR systems operating at 1.5 or 3.0 Tesla. For each indi-
vidual site, scanning was performed using the same
scanner and headcoil throughout the study. After acqui-
sition, scans were anonymized according to predefined
and centralized guidelines. Pseudonymised data were
subsequently transferred to the Image Analysis Centre
(IAC) of the VUmc in Amsterdam, the Netherlands. The
IAC collected, reviewed and stored the MR images. As part
of the quality control (e.g. being compared by the local
dummy scan), each MRI was centrally read by a neuroradi-
ologist or trained rater and rated according to a number of
basic visual rating scales: Medial Temporal Lobe Atrophy
(MTA) [32], Global Cortical Atrophy (GCA) [33], White
Matter Hyperintensities (WMH) [34]. In addition, lacunar
infarcts, cortical infarcts, and microbleeds were counted.
Blood
Samples of venous blood (10 cc clotted blood for serum
and 6 cc EDTA blood for plasma) were collected.
Samples were aliquoted into 0.5 cc samples and stored
at −80°C in each local biobank.
DNA
6 cc EDTA whole blood was collected for DNA extrac-
tion. DNA was isolated at each individual site. DNA iso-
lation was performed robotically, based on a salting out
method. After isolation and a quality control, the DNA
was stored in four cups at −80°C. Isolated DNA was
taken from the local biobanks and transported to the de-
partment of Clinical Genetics of the Maastricht Univer-
sity Medical Center. Apolipoprotein E (APOE) genotype
was determined on genomic DNA using the polymerase
chain reaction (PCR) technique [35]. Genotyping was
done blinded for all clinical data.
CSF
CSF was collected via a lumbar puncture in the interver-
tebral space at level L3/L4 or L4/L5. CSF was collected
and stored in polypropylene tubes. Three cc of CSF was
aliquoted in 0.5 cc samples and stored at −80°C until
analysis.
CSF samples were transported to the department of
Clinical Chemistry of the VUmc Amsterdam. The samples
were analyzed all at once, using the same batch of re-
agents. Ab42, tau, and ptau concentrations were measured
using commercially available single-parameter ELISA
methods (respectively Innotest® beta-amyloid (1–42) andInnotest ® hTAU-Ag; Innogenetics, Ghent, Belgium). CSF
analyses were done blinded for all clinical data.
Follow-up assessment
One and two years after baseline, patients were invited
for a follow-up assessment. At this time, the same clin-
ical and cognitive data were obtained. In addition, the
follow-up assessment two years after baseline also in-
cluded the collection of blood samples and an MRI of
the brain (Table 1). At follow-up, the course of cognitive
problems was investigated and the syndromal and etio-
logical diagnosis of each patient was based on the stan-
dardized criteria used at baseline.
Subjects who were not available for a follow-up assess-
ment were contacted by telephone, using a standardized
case record form (CRF) for telephone interview. This CRF
included information on survival, the CDR, information
about the reason for not participating in the follow-up
assessment, the course of the cognitive complaints, inter-
ference with daily living, reasons for eventual hospital visi-
tations, and whether a diagnosis of dementia was made
since the previous measurement. Recently, the consortium
has prolonged the clinical follow-up to at least three years,
so the study is ongoing.
Data collection, processing and storage
At baseline and follow-up, data are collected in a CRF
based on SOPs. Data of the CRFs are locally stored in
each center, based on a centrally defined Process Infor-
mation Model (PIM) (www.string-of-pearls.org). The use
of a PIM guarantees harmonized data collection across
UMCs, and across diseases for shared variables, like
demographics and medication use. After pseudonymisa-
tion, data were uploaded to a central data system. At a
central level, PSI facilitates collaborative research and
delivers a standardized Central Infrastructure, in which
all clinical data collected by the UMCs are managed at
one location.
Biological samples were processed and stored in each
local biobank according to the SOP for biomaterials. For
standardized analysis, biological samples were transported
on dry ice to central laboratories according to the SOP for
the transportation of biomaterials.
Ethical considerations
The Medical Ethics Review Committee of the VU University
Medical Center performed central approval of the study.
All local Medical Ethical Committees approved the local
performance of the study. The research is performed ac-
cording to the principles of the Declaration of Helsinki
(October 2008, www.wma.net) and in accordance with
the Medical Research Involving Human Subjects Act
and codes on ‘good use’ of clinical data and biological
samples as developed by the Dutch Federation of Medical
Box 2 MRI protocol
1. Sagittal 3D T1-weighted gradient-echo sequence (6–9 min).
E.g. MP-RAGE, SPGR, FFE
Correction for non-linear gradients (if applicable)
TE and TR according to local settings- giving good gray matter – white matter contrast
Slab thickness 180 mm, 180 partitions, 1.0 mm effective slice thickness
In-plane resolution 1.0 mm
2. 2D T2* gradient-echo sequence (3–5 min)
e.g. FLASH/FFE/SPGR, or (EPI-) SWI to obtain dark tissue background susceptible to T2* contrast –such as microbleedings.
TR≥ 500 ms, TE≥ 20 ms. Flip angle 20 degrees
Slice thickness 3 mm, no gap
Number of slices 48
In-plane resolution 0.5 – 1.0 mm
3. 2D T2-weighted FLAIR turbo/fast spin-echo (3–5 min)
TR 8,000 – 12,000 ms, TE 100–150 ms, TI 2,200 – 2,800 ms
Slice thickness 3 mm, no gap
Number of slices 48
In-plane resolution 0.5 – 1.0 mm
4. 2D T2-weighted turbo/fast spin-echo (3–5 min)
TR 2,000 - 4,000 ms, TE 80–120 ms
Slice thickness 3 mm, no gap
Number of slices 48
In-plane resolution 0.5 -1.0 mm
5. 2D Diffusion weighted imaging/EPI (30 sec-1 min)
Parallel Imaging on if possible (mandatory for 3 T)
TR 3,000-6,000 ms, TE 90–130 ms
Slice thickness < 5 mm, gap 10-30%
In plane resolution 2 mm b value (0/500/1000) or b value (0/900) or b value (0/1000) s/mm2.
5b. Include online calculated ADC maps if possible.
6. 2D Diffusion tensor imaging (optional) (6–8 min)
Parallel Imaging on if possible (mandatory for 3 T)
TR 8,000-14,000 ms, TE 80–100 ms
Number of slices 56–70 slices
In-plane resolution 2.0 – 2.5 mm.
30–60 diffusion weighted directions with b = 1000 s/mm2 , 5–6 scans with b = 0 s/mm2
Fat suppression ON
7. 2D Resting state fMRI (optional) (7–10 min)
3.0 Tesla scanner:
TR 1,800-2,200 ms, TE 30–40 ms, Flip Angle 80 degrees
Slice thickness 2.0 – 2.5 mm, gap 10%
Number of slices 38–54
In-plane resolution 2.0 – 2.3 mm
Number of volumes 200 (excluding run-in scans)
1.5 Tesla scanner:
TR 2,200-3,000 ms, TE 40–60 ms. Flip Angle 90 degrees
Slice thickness 2.5-3.0 mm, gap 10%
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Box 2 MRI protocol (Continued)
Number of slices 30–38
In-plane resolution 2.5 – 3.3 mm
Number of volumes 200 (excluding run-in scans)
All scans have full brain coverage except DTI, which has coverage of at least 140 mm and resting state fMRI that had coverage of at least 105 mm. All scans were
in the transverse orientation except the 3D T1w gradient echo sequence, which was in the sagittal orientation.
Table 3 APOE and CSF biomarker baseline descriptives by
syndrome diagnosis
Subjective complaints MCI Dementia
APOE genotype
APOE N 159 208 294
e4 noncarrier 96 (60%) 97 (47%) 137 (47%)
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tory framework in which ethical and legal rules and guide-
lines have been described. For guaranteeing the privacy of
the patients’ data and biomaterials, a pseudonymisation
service is delivered by a Trusted Third Party. All patients
gave written informed consent.
Results
Preliminary baseline results
In total more than 1000 patients have been included, of
which of a subsample of 665 patients, data were available
for the present analysis. Data from this subsample of pa-
tients were at present available and could be extracted
from the local UMCs and combined in one dataset, ac-
cording to the regulatory framework of PSI. Slightly less
than half of the patients were female. Average age was
70 ± 10 years old (Table 2). MMSE and CDR values show
that in the majority of patients cognition was mildly im-
paired (Table 2). In line with this, the syndrome diagnosis
was distributed as follows: subjective memory complaints
(24%), MCI (31%), and dementia (45%).
APOE genotype measurement was available for 661
(99%) patients and CSF biomarkers for 211 (32%) pa-
tients. Table 3 shows that patients with dementia were
more likely to be APOE e4 positive than patients with
subjective complaints, with patients with MCI in between.
Mean CSF concentrations of ab42 were lower while CSF
concentrations of (p)tau were higher in dementia pa-
tients than in patients with subjective complaints. For all
CSF biomarkers, the mean concentrations of MCI were
intermediate.
Discussion
The Pearl Neurodegenerative Diseases is a nationwide
network enabling centralized and uniform collection
of clinical data, blood, CSF and MRI of the brain inTable 2 Basic demographic and clinical variables of
subsample
N 665
Gender, F 276 (42%)
Age, years 70 ± 10; <65 year: 31%
MMSE 26 ± 3
CDR; 0; 0.5; 1 21%; 51%; 28%
Data are presented as n (%) or mean ± sd.patients from tertiary memory clinics. To date, this has
resulted in harmonization of data collection across centers
and in the inclusion of more than 1000 patients with cog-
nitive complaints, MCI or dementia. The current prelim-
inary biomarker study has shown feasibility of collecting
biomaterial from local biobanks for central analysis and
coupling with phenotypical data, showing the potential of
our data set.
The infrastructure of the Pearl Neurodegenerative
Diseases, taking advantage of the PSI Central Infrastructure
and regulatory framework, provides an excellent starting
point for future research, including collaborations with
other (inter)national projects focusing on neurodegenera-
tive diseases. The dataset makes it possible to perform na-
tionwide research into early diagnosis of neurodegenerative
diseases, in particular AD. The uniqueness of this data set
lies in the national coverage as our consortium includes
all Dutch UMCs. Among the most important achieve-
ments until now is the harmonization of diagnostic proce-
dures across academic memory centers. The use of SOP's
and therefore a strict uniform data collection guarantees
high quality of the data. We already see that other local
memory clinics start to adopt the PSI-procedures, result-
ing in further standardization of diagnostics across the
country and opening up further possibilities for collabor-
ating in research projects.
The infrastructure of the Pearl Neurodegenerative
Diseases is used as a framework for other studies, includinge4 heterozygous 51 (32%) 90 (43%) 124 (42%)
e4 homozygous 12 (8%) 19 (9%) 29 (10%)
CSF biomarkers
CSF biomarker N 60 67 84
Amyloid-beta 1-42 817 ± 252 692 ± 290 610 ± 258
Total tau 286 ± 170 473 ± 257 514 ± 277
Ptau 38 ± 18 53 ± 26 57 ± 26
Data are presented as mean ± sd. Please note that while raw CSF biomarker
values are presented, statistical analyses were performed using
log-transformed values.
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data and biomaterial (specifically CSF) have already been
incorporated in large international consortia (BIOMARK-
APD; EMIF-AD) in the context of the Joint Programming
of Neurodegenerative Diseases (JPND; www.neurodegene
rationresearch.eu) and Innovative Medicines Initiative (IMI;
www.imi.europa.eu) of the European Union.
Several other multicentre initiatives have collected data
to study the value of new biomarkers for early identifica-
tion of AD and related disorders. The Alzheimer’s Disease
Neuroimaging Initiative (ADNI) in North America aims
to identify neuroimaging measures and biomarkers associ-
ated with cognitive and functional changes in healthy eld-
erly subjects and in subjects who have MCI and AD
(www.adni-info.org). The Australian Imaging, Biomarkers
and Lifestyle (AIBL) study of ageing aims to study bio-
markers, cognitive characteristics and health and lifestyle
factors determine AD (www.aibl.csiro.au). The Swedish
Brain Power Network (www.swedishbrainpower.se) aims
to enhance early diagnosis, treatment and care for patients
with neurodegenerative diseases, including AD, Parkinson's
Disease and amyotrophic lateral sclerosis. The Pearl
Neurodegenerative Diseases adds to these other programs
by firmly consolidating research in a clinical setting. The
implementation of SOPs in clinical routine guarantees
maximally efficient use of data and is thought to allow
swift feedback of research results into clinical practice.
Among the limitations of the Pearl Neurodegenerative
diseases is the potential referral bias as a consequence of
inclusion of patients at tertiary UMC. The study results
are generalizable to a population of patients referred to an
academic memory clinic, but not to patients referred to a
general practitioner, or any other community hospital or
from the general population. Our sample provides a good
reflection however of the patient population for which
biomarkers might have high relevance. In addition, we in-
cluded a broad range of patients, covering the continuum
of cognitive decline from subjective complaints until the
clinical diagnosis of dementia, but not healthy controls.
One might argue, however, that for the aims of the present
Pearl Neurodegenerative Diseases that the comparison of
patients with dementia with patients with subjective com-
plaints has more clinical relevance than comparing pa-
tients with dementia to healthy controls.
Based on our recent experience, we have continued
patient inclusion to enlarge our data set. In addition, the
consortium has decided to prolong clinical follow-up to
at least three years, to allow the study of biomarkers in
relation to long-term follow-up.
Conclusion
In conclusion, the deep phenotyping in combination with
longitudinal data collection, the multi-center set up, and the
firm basis in regular patient care, resulting in a sample ofreal life patients, rather than a highly selected research sam-
ple, make our sample attractive for future studies aiming to
develop diagnostic biomarkers, prognostic biomarkers, ‘ther-
anostic’ (i.e. predicting response to therapy) biomarkers and
biomarkers aiming to monitor disease progression. As such,
the Pearl Neurodegenerative Diseases forms an ideal real
life sample to host studies aiming to improve trial de-
sign and to validate new targets of therapy.
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